Jerome Rossert

Summary

Country: France

Publications

  1. ncbi Effect of early correction of anemia on the progression of CKD
    Jerome Rossert
    Paris Descartes University, INSERM U652, AP HP, Georges Pompidou European Hospital, Paris, France
    Am J Kidney Dis 47:738-50. 2006
  2. ncbi Role of anemia in progression of chronic kidney disease
    Jerome Rossert
    Paris Descartes University School of Medicine, Paris, France
    Semin Nephrol 26:283-9. 2006
  3. ncbi Erythropoietin-induced, antibody-mediated pure red cell aplasia
    Jerome Rossert
    Hopital Europeen Georges Pompidou, Paris, France
    Eur J Clin Invest 35:95-9. 2005
  4. ncbi Antibody-mediated pure red cell aplasia (PRCA) treatment and re-treatment: multiple options
    Jerome Rossert
    Department of Nephrology, Georges Pompidou European Hospital AP HP, 20 rue Leblanc, 75015 Paris, France
    Nephrol Dial Transplant 20:iv23-26. 2005
  5. ncbi Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients
    Jerome Rossert
    Paris Descartes University and AP HP Georges Pompidou European Hospital, Paris, France
    Nephrol Dial Transplant 22:794-800. 2007
  6. ncbi [The diabetic patient: renal insufficiency like other kidney failures?]
    Jerome Rossert
    Universite Paris Descartes, AP HP hôpital européen Georges Pompidou et INSERM unité 652, Paris, France
    Nephrol Ther 2:S187-9. 2006
  7. ncbi [Diagnosis and treatment of pure red-cell aplasia induced by erythropoiesis stimulating agents]
    Jerome Rossert
    AP HP HEGP, Universite Paris Descartes, INSERM U652, Paris, France
    Nephrol Ther 2:S283-6. 2006
  8. ncbi Epoetin-induced autoimmune pure red cell aplasia
    Nicole Casadevall
    Department of Hematology, Hotel Dieu and INSERM U362, Paris, France
    J Am Soc Nephrol 16:S67-9. 2005
  9. ncbi Recommendations on haematological criteria for the diagnosis of epoetin-induced pure red cell aplasia
    Nicole Casadevall
    Service d Hematologie Biologique, Hopital Hotel Dieu, Paris, France
    Eur J Haematol 73:389-96. 2004
  10. ncbi Anemia management and the delay of chronic renal failure progression
    Jerome Rossert
    University of Paris VI, Tenon Hospital AP HP and INSERM U489, Paris, France
    J Am Soc Nephrol 14:S173-7. 2003

Collaborators

Detail Information

Publications17

  1. ncbi Effect of early correction of anemia on the progression of CKD
    Jerome Rossert
    Paris Descartes University, INSERM U652, AP HP, Georges Pompidou European Hospital, Paris, France
    Am J Kidney Dis 47:738-50. 2006
    ..This study is designed to assess the effect of early and complete correction of anemia by using recombinant human erythropoietin (epoetin) alfa on the progression of chronic kidney disease (CKD)...
  2. ncbi Role of anemia in progression of chronic kidney disease
    Jerome Rossert
    Paris Descartes University School of Medicine, Paris, France
    Semin Nephrol 26:283-9. 2006
    ..However, only a large, randomized, prospective trial will be able to establish if anemia correction can slow the progression of CKD effectively...
  3. ncbi Erythropoietin-induced, antibody-mediated pure red cell aplasia
    Jerome Rossert
    Hopital Europeen Georges Pompidou, Paris, France
    Eur J Clin Invest 35:95-9. 2005
    ..Retrospective analysis of PRCA cases has shown that immunosuppressive therapy can induce a disappearance of anti-erythropoietin antibodies in most patients. Eur J Clin Invest 2005; 35 (Suppl. 3): 95-99...
  4. ncbi Antibody-mediated pure red cell aplasia (PRCA) treatment and re-treatment: multiple options
    Jerome Rossert
    Department of Nephrology, Georges Pompidou European Hospital AP HP, 20 rue Leblanc, 75015 Paris, France
    Nephrol Dial Transplant 20:iv23-26. 2005
    ..However, one should be extremely cautious when deciding to re-treat a patient with ESA, due to the small number of reported cases and the possibility of publication bias...
  5. ncbi Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients
    Jerome Rossert
    Paris Descartes University and AP HP Georges Pompidou European Hospital, Paris, France
    Nephrol Dial Transplant 22:794-800. 2007
    ..The required erythropoiesis-stimulating agent (ESA) dose varies when correcting anaemia in chronic kidney disease (CKD) patients. This analysis was performed to identify the prevalence of and factors associated with ESA hyporesponsiveness...
  6. ncbi [The diabetic patient: renal insufficiency like other kidney failures?]
    Jerome Rossert
    Universite Paris Descartes, AP HP hôpital européen Georges Pompidou et INSERM unité 652, Paris, France
    Nephrol Ther 2:S187-9. 2006
    ..Finally, small studies suggest that patients with diabetic nephropathy could have lower serum concentrations of parathyroid hormone than patients with non-diabetic nephropathy and similar glomerular filtration rate...
  7. ncbi [Diagnosis and treatment of pure red-cell aplasia induced by erythropoiesis stimulating agents]
    Jerome Rossert
    AP HP HEGP, Universite Paris Descartes, INSERM U652, Paris, France
    Nephrol Ther 2:S283-6. 2006
    ..Isolated case reports suggest that, at least in some patients, treatments with ESA can be resumed after recovery from antibody-mediated pure red-cell aplasia...
  8. ncbi Epoetin-induced autoimmune pure red cell aplasia
    Nicole Casadevall
    Department of Hematology, Hotel Dieu and INSERM U362, Paris, France
    J Am Soc Nephrol 16:S67-9. 2005
    ..The incidence rate seems now to be back to the baseline level. The change in formulation of epoetin a sold outside the United States seems to be the cause of these antibodies...
  9. ncbi Recommendations on haematological criteria for the diagnosis of epoetin-induced pure red cell aplasia
    Nicole Casadevall
    Service d Hematologie Biologique, Hopital Hotel Dieu, Paris, France
    Eur J Haematol 73:389-96. 2004
    ....
  10. ncbi Anemia management and the delay of chronic renal failure progression
    Jerome Rossert
    University of Paris VI, Tenon Hospital AP HP and INSERM U489, Paris, France
    J Am Soc Nephrol 14:S173-7. 2003
    ..The results of two small prospective studies and of a retrospective one also suggest that treatment with epoetin may have such protective effects...
  11. ncbi [How to improve estimation of renal function in the elderly]
    Marc Froissart
    Universite Paris Descartes, Hopital Europeen Georges Pompidou, INSERM U652, 75908 Paris
    Rev Prat 55:2223-9. 2005
    ..GFR tends to decrease with age, but it should be 60 mL/min/1,73 m2 or higher in all subjects who do not suffer from kidney disease, regardless of age...
  12. ncbi Anti-erythropoietin antibodies and pure red cell aplasia
    Jerome Rossert
    Department of Nephrology, Tenon hospital and Pierre and Marie Curie University, Paris, France
    J Am Soc Nephrol 15:398-406. 2004
  13. ncbi Predictive performance of the modification of diet in renal disease and Cockcroft-Gault equations for estimating renal function
    Marc Froissart
    Department of Physiology and Biophysics, Georges Pompidou European Hospital, 20 rue Leblanc, 75015 Paris, France
    J Am Soc Nephrol 16:763-73. 2005
    ..Finally, 29.2 and 32.4% of subjects were misclassified when the CG and MDRD formulas were used to categorize subjects according to the Kidney Disease Outcomes Quality Initiative chronic kidney disease classification, respectively...
  14. ncbi Pitfalls of measuring total blood calcium in patients with CKD
    Cedric Gauci
    Departement de Physiologie, Hopital Europeen Georges Pompidou, 20 40 rue Leblanc, F 75015 Paris, France
    J Am Soc Nephrol 19:1592-8. 2008
    ..In conclusion, albumin-corrected tCa does not predict iCa better than noncorrected tCa. Moreover, both noncorrected and albumin-corrected tCa concentrations poorly predict hypo- or hypercalcemia in patients with CKD...
  15. ncbi In vivo inhibition of osteoblastic metalloproteinases leads to increased trabecular bone mass
    Valerie Geoffroy
    INSERM U349, Hopital Lariboisiere, Paris, France
    J Bone Miner Res 19:811-22. 2004
    ..These mice displayed increased trabecular bone volume and decreased bone turnover. This model provides evidence of the role played by the MMPs in bone remodeling and balance...
  16. ncbi Transgenic mice expressing nitroreductase gene under the control of the podocin promoter: a new murine model of inductible glomerular injury
    Guillaume Macary
    INSERM UMRS 872, Centre de Recherche des Cordeliers, Equipe 3, 75006, Paris, France
    Virchows Arch 456:325-37. 2010
    ..This model of podocyte injury in transgenic mice provides new insights into the cellular mechanisms of podocytopathies and their progression to scarring...
  17. ncbi Long-term evolution and determinants of renal function in HIV-infected patients who began receiving combination antiretroviral therapy in 1997-1999, ANRS CO8 APROCO-COPILOTE
    Catherine Leport
    Universite Paris Diderot, Paris 7, UFR Medecine, AP HP, site Bichat, France
    Clin Infect Dis 49:1950-4. 2009
    ..Kidney function should be monitored in patients previously exposed to indinavir...